Paper Details

  1. Home
  2. Paper Details

mTOR inhibitors for hepatocellular cancer: a forward-moving target.

Author: TreiberGerhard

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

mTOR is a protein that plays a key role in cell growth and the formation of blood vessels. In about half of people with liver cancer, the mTOR pathway is overactive. mTOR inhibitors are medications that block the mTOR pathway and have been shown to reduce tumor growth and blood vessel formation in laboratory studies. Clinical trials are ongoing to evaluate the use of mTOR inhibitors in treating advanced liver cancer.
Paper Details　
Original Abstract of the Article :
mTOR is a central regulator of cell growth and angiogenesis. The mTOR pathway is activated in 40-50% of patients with hepatocellular cancer (HCC). In different models (i.e., hepatoma cell lines and implanted HCC tumors in rats), mTOR inhibitors (mTORIs) were effective in reducing cell growth and tum...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1586/14737140.9.2.247

データ提供：米国国立医学図書館（NLM）

mTOR Inhibitors for Hepatocellular Cancer: A Forward-Moving Target

Hepatocellular cancer (HCC) presents a significant challenge in cancer treatment. The mTOR pathway, a critical regulator of cell growth and angiogenesis, is frequently activated in HCC patients. This research explores the potential of mTOR inhibitors (mTORIs) as a therapeutic option for HCC, examining their effects on cell growth, tumor vascularity, and potential synergistic interactions with other treatment modalities.

The study reviews preclinical and clinical data on mTORIs in HCC, highlighting their efficacy in reducing cell growth and tumor vascularity in various models. The authors discuss the potential benefits of combining mTORIs with other therapies, such as chemotherapeutic agents, growth hormone inhibitors, and angiogenesis inhibitors.

The research emphasizes the potential of mTORIs in treating HCC, particularly when combined with other therapies. However, the authors acknowledge the need for further clinical trials to establish definitive evidence for their effectiveness and safety.

Targeting the mTOR Pathway in HCC

This research sheds light on the mTOR pathway's role in HCC and the potential of mTORIs in targeting this pathway to effectively treat the disease. The study emphasizes the need for further research to explore the optimal use of mTORIs, alone or in combination with other therapies, to optimize patient outcomes.

A Promising Avenue for HCC Treatment

The study's exploration of mTOR inhibitors as a therapeutic target for HCC offers a promising avenue for future research and clinical development. This research highlights the potential of targeting specific molecular pathways to effectively treat cancer and improve patient survival.

Dr.Camel's Conclusion

Just like a camel traversing a vast desert, this research navigates the challenging landscape of HCC treatment, exploring the potential of mTOR inhibitors as a potent weapon against this disease. The findings suggest that targeting the mTOR pathway, either alone or in combination with other therapies, holds promise for improving patient outcomes. This research encourages further exploration of this promising avenue, with the hope of developing more effective and targeted therapies for HCC.

Date :
  1. Date Completed 2009-04-15
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

19192962

DOI: Digital Object Identifier

10.1586/14737140.9.2.247

Related Literature

Article Analysis
・Side Effects of temsirolimus
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.